Search results for: Pricing and Reimbursement
Filter search results
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
…States; it is between national affordability objectives and global innovation incentives, and it is visible across Europe. Governments want innovative medicines, thriving life-sciences sectors, investment and jobs and to lower…
Evidence on Valued Based Pricing and Reimbursement Schemes
30 September 2011
…and performance-based reimbursement. Dr. Mestre-Ferrandiz Despite the potential importance of value-based schemes for influencing the pricing, reimbursement and use of pharmaceuticals, the literature contains remarkably little hard evidence about their…
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
…therefore especially sensitive to regulatory and policy changes. However, regulatory incentives for orphan drug research and development (R&D) are often not matched by Health Technology Assessment (HTA) and Pricing and…
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
…sustainable, and the innovation pipeline is robust. In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of…
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
…shortages, policymakers should recognise the value of supply diversification, effective market competition, and supply-chain resilience, supported by incentives at regulatory, health technology assessment, and pricing and reimbursement levels. The Dynamics…
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
…regulatory pathways to support timely access to promising therapies in areas of high unmet medical need. On the other hand, Health Technology Assessment (HTA) and pricing and reimbursement (P&R) processes…
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
…practices should be shared and that, to seize opportunities, companies should monitor and respond to public sentiment, proactively address any negative issues, and invest in R&D and technology to deal…
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
…Health Technology Assessment; HTD, health technology developer; JCA, Joint Clinical Assessments; JSC, Joint Scientific Consultation; NOMA, Norwegian Medical Products Agency; P&R, pricing and reimbursement; TLV, Dental and Pharmaceutical Benefits Agency Current and Emerging Challenges Implementation of…
Around the World in HTAs: Spain – Closer than ever, but not quite yet
8 July 2026
…reforms – a draft Royal Decree on medicines pricing and reimbursement and a new Medicines and Medical Devices Bill – are still moving through the policy pipeline. Together, these texts…